Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00209079
Status:
TERMINATED
Last Update Posted:
2007-12-31
First Post:
2005-09-14
Brief Title:
Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma
Sponsor:
Emory University
Organization:
Emory University
Study Overview
Official Title:
Phase II Trial of Gleevec Imatinib Mesylate and Taxotere Docetaxel as a Combined Regimen for Advanced Gastric Adenocarcinoma
Status:
TERMINATED
Status Verified Date:
2007-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated 41707 Drug sponsor withdrew
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to test the combination of Gleevec also known as imatinib mesylate and Taxotere also known as docetaxel in patients with incurable stomach cancer This study is being performed to see if the combination of Gleevec and Taxotere is an effective treatment for incurable stomach cancer with minimal side effects
Detailed Description:
The purpose of this trial is to test the combination of Gleevec also known as imatinib mesylate and Taxotere also known as docetaxel in patients with incurable stomach cancer Gleevec is a pill form of chemotherapy and is indicated for the treatment of adult patients with chronic myeloid leukemia CML and gastrointestinal stromal tumors GIST It is considered experimental for the treatment of stomach cancer Taxotere docetaxel is a chemotherapy which is injected into the vein It is approved for breast and lung cancer but has been shown to shrink many different types of tumors Taxotere has been shown to shrink stomach cancer in about 20 - 30 of patients treated with Taxotere only This study is being performed to see if the combination of Gleevec and Taxotere is an effective treatment for incurable stomach cancer with minimal side effects
Treatment on this study consists of two drugs Gleevec and Taxotere Patients will be take four tablets of Gleevec daily throughout the study After one week of Gleevec patients will then begin receiving doses of Taxotere intravenously once a week for two weeks in a row followed by one week without Taxotere
Treatment on this study consists of two drugs Gleevec and Taxotere Patients will be take four tablets of Gleevec daily throughout the study After one week of Gleevec patients will then begin receiving doses of Taxotere intravenously once a week for two weeks in a row followed by one week without Taxotere
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None